Top Markets
Coin of the day
Dong-A ST Co., Ltd. Dong-A ST Co., Ltd.

Dong-A ST Co., Ltd.

170900
주식 순위 #17345
Dong-A ST Co., Ltd. is a global enterprise focused on the research,... Dong-A ST Co., Ltd. is a global enterprise focused on the research, development, production, and commercialization of a broad spectrum of pharmaceutical products and medical devices. The company's diverse portfolio of ethical drugs targets various medical conditions, including tuberculosis (with treatments like Closerin and Terizidone), neutropenia in chemotherapy patients (such as Dulastin and Leucostim), and anemia stemming from chronic renal failure (Eporon). Its robust oncology offerings feature Gemcit for cancers affecting the lung, pancreas, breast, bladder, and ovaries; Mainta for non-small cell lung cancer and malignant pleural mesothelioma; and Monotaxel, indicated for breast, prostate, head, neck, and gastric adenocarcinoma, among others. Additionally, Dong-A ST provides solutions for infertility and anovulation (Gonadopin), growth hormone deficiency and idiopathic short stature (Growtropin II), functional dyspepsia (Motilitone), gastritis (Stillen), diabetes (Suganon), and erectile dysfunction (Zydena). The company also actively participates in pharmaceutical licensing, encompassing both the acquisition and out-licensing of drugs. Its medical device segment includes advanced technological equipment, customized products, and specialized artificial cardiac circuit sets essential for complex open-heart surgeries. Dong-A ST Co., Ltd. was established in 1932 and is headquartered in Seoul, South Korea.
주가
$25.52
시가총액
$246.07M
변동 (1일)
-2.25%
변동 (1년)
-4.13%
국가
KR
거래 Dong-A ST Co., Ltd. (170900)

카테고리

Dong-A ST Co., Ltd. (170900)의 수익
2026 기준 수익 TTM: 0
Dong-A ST Co., Ltd.의 최신 재무 보고서에 따르면 회사의 현재 수익은 0입니다. 2026년에 회사는 0의 수익을 올렸으며 이는 2026년의 수익 0과 동일입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Dong-A ST Co., Ltd.의 수익 기록 (2026 ~ 2026)
연말 수익
연도 수익 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 수익